| Literature DB >> 17980044 |
Lai-Shan Tam1, Ping-Chung Leung, Tena K Li, Lang Zhang, Edmund K Li.
Abstract
BACKGROUND: In planning a randomized controlled trial of acupuncture, we conducted a pilot study using validated outcome measures to assess the feasibility of the protocol, and to obtain preliminary data on efficacy and tolerability of 3 different forms of acupuncture treatment as an adjunct for the treatment of chronic pain in patients with Rheumatoid arthritis (RA).Entities:
Mesh:
Year: 2007 PMID: 17980044 PMCID: PMC2174514 DOI: 10.1186/1472-6882-7-35
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Figure 1A special device using a 2 cm cube of foam material adherent to the skin around the acupuncture point for mounting the acupuncture needle. The recipient would not be able to see the level of entry of the needle since the tip of the needle was hidden by the adherent cylinder of foam.
Figure 2The anatomical location of the six acupuncture points.
Demographics and current medications of patients with RA
| Electro-Acupuncture (EA) (N = 12) | Traditional Acupuncture (TCA) (N = 12) | Sham Acupuncture (Sham) (N = 12) | |
| Age, mean ± SD years | 56.4 ± 8.5 | 58.1 ± 12.0 | 57.6 ± 8.3 |
| Disease duration, mean ± SD years | 8.4 ± 5.6 | 10.8 ± 6.2 | 8.1 ± 6.9 |
| Male: Female | 1:11. | 2:10 | 4:8 |
| Rheumatoid factor positive, n (%) | 7 (54) | 11 (85) | 8 (61) |
| Erosion on x-rays (%) | 8 (61) | 8 (61) | 9 (69) |
| NSAIDs, n (%) | 7 (54) | 6 (46) | 8 (61) |
| Methotrexate, n (%) | 10 (77) | 8 (61) | 9 (69) |
| Hydroxycloroquine, n (%) | 2 (15) | 1 (7.9) | 0 (0) |
| Sulphasalazine, n (%) | 2 (15) | 4 (31) | 2 (15) |
| Leflunomide, n (%) | 3 (23) | 3 (23) | 4 (31) |
| Prednisolone, n (%) | 2 (15) | 1(7.9) | 1 (8) |
| Analgesics, n (%) | 4 (31) | 0 (0) | 4 (31) |
NSAID = non-steroidal anti-inflammatory drugs. P > 0.05 comparing all 3 groups in all the variables.
Changes in the American College of Rheumatology (ACR) components and DAS 28 scores for the three groups of patients after 10 weeks
| 6.0 ± 2.1 | 5.7 ± 2.3 | 5.4 ± 2.8 | 5.1 ± 2.9 | 6.5 ± 2.0 | 5.1 ± 1.9 | |
| 3.0 (0.3–6.0) | 3.5 (1.3–4.0) | 6.5 (4.3–9.8) | 4.0 (2.3–6.8) | 4.0 (2.0–7.8) | 3.5 (1.3–5.0) | |
| 9.0 (3.0–13.5) | 3.5 (2.0–9.0)* | 13.0 (8.0–19.0) | 9.0 (4.3–12.5)* | 6.5 (4.0–17.3) | 6.0 (2.0–12.5) | |
| 6.4 ± 2.2 | 5.8 ± 2.1 | 6.4 ± 2.2 | 5.0 ± 2.4* | 6.8 ± 2.3 | 5.0 ± 2.4* | |
| 5.3 ± 2.1 | 4.0 ± 2.1* | 6.0 ± 1.8 | 4.7 ± 2.1 | 5.1 ± 2.0 | 4.8 ± 2.3 | |
| 59 ± 33 | 58 ± 36 | 53 ± 26 | 59 ± 26 | 64 ± 41 | 66 ± 43 | |
| 12.7 (5.6–46.7) | 13.3 (5.6–38.2) | 8.1 (4.3–24.4) | 12.7 (5.1–43.1) | 12.2 (5.0–43.6) | 10.2 (4.9–36.2) | |
| 1.5 ± 0.7 | 1.3 ± 0.7 | 1.6 ± 0.6 | 1.5 ± 0.7 | 1.4 ± 1.0 | 1.3 ± 0.9 | |
| 4.5 ± 1.0 | 4.4 ± 1.0 | 4.8 ± 1.2 | 4.7 ± 1.1 | 4.5 ± 1.3 | 4.4 ± 1.1 | |
Data were expressed as mean ± SD or median (IQR). VAS = visual analog scale. ESR = erythrocyte sedimentation rate. CRP = C-reactive protein. HAQ = health assessment questionnaire. DAS 28 = disease activity score using the 28 joint counts. * p < 0.05 comparing before and after treatment.
Figure 3Patients progress through the trial.